FDA Issues Complete Response Letter to Supernus for SPN-830, a Potential Treatment for Motor Fluctuations in Parkinson Disease

Posted on by admin
1 min read

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours